CLAIMS

1. A method for treating a cancer in an individual comprising administering to the individual a combination therapy which comprises an antagonist of a Programmed Death 1 protein (PD-1) and a VEGFR inhibitor, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is *N*-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

2. The method of claim 1, wherein the individual is a human.

3. The method of claim 1 or 2, wherein the cancer is a solid tumor.

4. The method of claim 1 or 2, wherein the cancer is renal cell carcinoma.

5. The method of any of claims 1 to 4, wherein the PD-1 antagonist is MK-3475 and the VEGFR inhibitor is axitinib.

6. A medicament comprising an antagonist of a Programmed Death 1 protein (PD-1) for use in combination with a VEGFR inhibitor for treating a cancer in an individual, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is *N*-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

7. A medicament comprising a VEGFR inhibitor for use in combination with an antagonist of a Programmed Death 1 protein (PD-1) for treating a cancer in an individual, wherein the VEGFR inhibitor is *N*-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof, and further wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22.

8. The medicament of claim 6 or 7, wherein the individual is a human.

9. The medicament of any of claims 6 to 8, wherein the cancer is a solid tumor that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

10. The medicament of any of claims 6 to 8, wherein the cancer is renal cell carcinoma.

11. The medicament of any of claims 6 to 10, wherein the PD-1 antagonist is MK-3475 and the VEGFR inhibitor is axitinib.

12. The medicament of claim 11, wherein the MK-3475 is formulated as a liquid medicament which comprises 25 mg/ml MK-3475, 7% (w/v) sucrose, 0.02% (w/v) polysorbate 80 in 10 mM histidine buffer pH 5.5 and axitinib is formulated as a 1 mg tablet or a 5 mg tablet.

13. A kit which comprises a first container, a second container and a package insert, wherein the first container comprises at least one dose of a medicament comprising an antagonist of a Programmed Death 1 protein (PD-1), the second container comprises at least one dose of a medicament comprising a VEGFR inhibitor, and the package insert comprises instructions for treating an individual for cancer using the medicaments, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is *N*-methyl-2-[3-((E)-2-pyridin-2-yl-vinyl)-1*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

14. The kit of claim 13, wherein the instructions state that the medicaments are intended for use in treating an individual having a cancer that tests positive for PD-L1 expression by an immunohistochemical (IHC) assay.

15. The kit of claim 13 or 14, wherein the individual is a human.

16. The kit of any of claims 13 to 15, wherein the PD-1 antagonist is MK-3475 formulated as a liquid medicament and the VEGFR inhibitor is axitinib formulated as a 1 mg tablet or a 5 mg tablet.

17. The method, use or kit of any of claims 1-3, 5-9, or 11-15, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin's lymphoma (HL), mantle cell lymphoma

~~(MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).~~

~~18. The method, use or kit of any of the above claims, wherein the cancer is advanced renal cell carcinoma.~~

~~19. A method for treating a human individual diagnosed with a cancer, comprising administering to the individual a combination therapy which comprises MK-3475 and axitinib, wherein (a) axitinib is administered at a dose of 5 mg BID and MK-3475 is administered at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W or (b) axitinib is administered at a dose of 3 mg BID and MK-3475 is administered at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W.~~

~~20. A medicament comprising:~~

~~(a) MK-3475 for use in combination with axitinib for treating a cancer in a human individual by a method comprising administering to the individual (i) axitinib at a dose of 5 mg BID and MK-3475 at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W or (ii) axitinib at a dose of 3 mg BID and MK-3475 at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W; or~~

~~(b) axitinib for use in combination with MK-3475 for treating a cancer in a human individual by a method comprising administering to the individual (a) axitinib at a dose of 5 mg BID and MK-3475 at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W or (b) axitinib at a dose of 3 mg BID and MK-3475 at a dose selected from the group consisting of 1 mg/kg Q3W, 2 mg/kg Q3W and 200 mg Q3W.~~

CLAIMS

1. Use of an antagonist of a Programmed Death 1 protein (PD-1) and a vascular endothelial growth factor receptor (VEGFR) inhibitor for the manufacture of a medicament for combination therapy treatment of a cancer in an individual, wherein the PD-1 antagonist is an anti-PD-1 monoclonal antibody which comprises a heavy chain and a light chain, wherein the heavy and light chains comprise SEQ ID NO:21 and SEQ ID NO:22, respectively, and further wherein the VEGFR inhibitor is N-methyl-2-[3-((E)-2-pyridin-2-yl- vinyl)- l*H*-indazol-6-ylsulfanyl]-benzamide or a pharmaceutically acceptable salt thereof.

2. The use according to claim 1, wherein the individual is a human.

3. The use according to claim 1 or 2, wherein the cancer is a solid tumor.

4. The use according to claim 1 or 2, wherein the cancer is renal cell carcinoma.

5. The use according to any one of claims 1 to 4, wherein the PD-1 antagonist is pembrolizumab and the VEGFR inhibitor is axitinib.

6. The use of any one of claims 1-3, wherein the cancer is bladder cancer, breast cancer, clear cell kidney cancer, head/neck squamous cell carcinoma, lung squamous cell carcinoma, malignant melanoma, non-small-cell lung cancer (NSCLC), ovarian cancer, pancreatic cancer, prostate cancer, renal cell cancer, small-cell lung cancer (SCLC), triple negative breast cancer, acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), chronic myeloid leukemia (CML), diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, Hodgkin’s lymphoma (HL), mantle cell lymphoma (MCL), multiple myeloma (MM), myeloid cell leukemia-1 protein (Mcl-1), myelodysplastic syndrome (MDS), non-Hodgkin's lymphoma (NHL), or small lymphocytic lymphoma (SLL).